Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...
Amgen and Merck: The P/E ratio
Within that group, biotechnology giant Amgen (NASDAQ: AMGN) has been the best-performing stock in 2025, returning an ...
Medscape5h
FDA Approves Fourth Denosumab Biosimilar
Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
Fierce Biotech1h
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...
The Lund Report14h
Oregon won’t set price caps on prescription drugs — for now
A key state lawmaker says that the push for Oregon to set price limits on increasingly costly prescription drugs will have to ...
Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History”
Senator Ron Wyden (D-Ore.), a senior member of the Senate Finance Committee, accused Pfizer (PFE) of carrying out what he ...
Managed Healthcare Executive16h
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
These Powerful Weight Loss Drugs Are Transforming Obesity Treatment – But Not Without Risks
Are we truly on the brink of a cure for obesity? Or could neglecting the root causes risk worsening the very problems we seek ...
PipelineReview.com21h
Fresenius Receives FDA Approval for their Denosumab Biosimilars and Secures Global Settlement Agreement
LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...
Weekly Recap: 15 Health Press Releases You Need to See
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
Leading Chinese Biotech Company Innovent Is on Track to Profitability
Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...